Priveterra (NASDAQ:PMGM) announced this morning what it has been cooking up through seven adjournments of its special meeting to complete its combination with AEON Biopharma – up to $105 million in new funding through a mix of facilities.
Of this, $20 million is to follow the terms of the deal’s existing A-1 notes, joining $20 million in investments made by existing AEON investors at $7 per share. A new investor ACM ASOF VIII has also agreed to purchase 1,000,000 shares for $7 per share and will be further compensated with 75,000 newly issued shares.
Importantly, this $47 million in note financing alone should be enough to cover the transaction’s $45 million minimum cash condition. But, Priveterra nonetheless announced it would adjourn its special meeting an eighth time from 4 pm ET today to 4:30 pm ET July 3 to continue talk to shareholders.
This is something of an awkward meeting time late in the day sandwiched between a weekend and the Fourth of July holiday. Priveterra also has until August 11 to complete its deal, so SPACland would likely not be shocked at a ninth rain check next week.
Nonetheless, the bulk of the new financing announced today is to potentially come in the form of forward-purchase agreements with ACM ARRT and Polar Multi-Strategy Fund. These investors are to purchase up to 7,500,000 shares in an OTC prepaid equity arrangement.
These investors will be compensated for this on a per share basis at Priveterra’s redemption rate shortly after close. From then on, these investors may sell shares and terminate the agreements coverage of them. At such times they are to pay AEON the lower of $7 or 30-day VWAP per share.
The higher share price for the forward purchase agreements could counteract the possibility that the note investments at $7 could trigger Priveterra’s $9.20 Crescent Term. Such purchases would have to represent more than 60% of total equity proceeds and the SPAC’s stock would have to hit a pre-close 20-day VWAP under $9.20 in order for this to take effect.
Priveterra inked its $201.8 million business combination with drug developer AEON on December 13. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
As the 2025 market environment settles in, SPACs have an increasingly defined role within the capital markets ecosystem, more often bringing midcap companies public, while traditional IPO deal flow has skewed smaller over time. And, as this new analysis shows, SPACs have been frequently offering investors higher upside when these companies excel. Of course, as...
At the SPAC of Dawn Despite the jitters sent through the market ahead of today’s festival of tariff implementations, SPACs have shown themselves to be unconcerned with “Liberation Day” as two teams priced their IPOs and will debut in the eye of the storm later today. That makes for four new SPAC listings on the...
Soulpower Acquisition Corporation (NYSE:SOUL.U) announced the pricing of its upsized $220 million IPO and its units are expected to begin trading on the NYSE under the symbol “SOUL.U”, Wednesday, April 2, 2025. The Company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution but will focus...
Sizzle Acquisition Corp. II (NASDAQ: SZZLU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “SZZLU”, Wednesday, April 2, 2025. Sizzle II plans to search for a target in a range of industries and combine with an established business of scale poised...
In March 2025, SPAC activity remained largely in line with February, though notable shifts emerged across extensions, announced transactions, and completions. Extension activity remained steady, with a slight increase in the number of SPACs seeking additional time. However, later-stage extensions became more common, reflecting a maturing SPAC landscape. Announced transaction volume continued to be weak,...